MB49 Syngeneic Model Service for Bladder Cancer

The MB49 syngeneic model is the reference immunocompetent platform for bladder cancer research, engrafting a chemically induced murine urothelial carcinoma line into C57BL/6 hosts so that tumor–immune interactions remain fully intact. Alfa Cytology offers this model as a comprehensive preclinical package — authenticated cell banking, both subcutaneous and intravesical implantation formats, intravesical treatment administration, scheduled monitoring, and complete terminal histopathology — giving sponsors a versatile, translationally relevant bladder cancer system without building syngeneic model capability in-house.

Overview of MB49 Syngeneic Model for Bladder Cancer

MB49 is the most widely used murine bladder cancer cell line in existence, and its history stretches back nearly half a century to the laboratory of Leonard Franks at the Imperial Cancer Research Fund. In the foundational 1979 study, primary bladder epithelial cells from a C57BL/6 mouse were exposed in culture for 24 hours to 7,12-dimethylbenz[a]anthracene (DMBA), a polycyclic aromatic hydrocarbon carcinogen; the transformed cells were then transplanted back into syngeneic hosts, where they produced progressively growing urothelial carcinomas. Notably, although the original donor was male, the cell line was subsequently found to have lost its Y chromosome during extended culture — a quirk it shares with a notable fraction of human bladder tumors. As a syngeneic line of H-2^b haplotype matched to C57BL/6 hosts, MB49 preserves an intact immune system, which distinguishes it from human xenograft platforms and has made it the default choice for intravesical BCG studies, checkpoint inhibitor evaluation, adenoviral immunogene therapy, and photothermal-immunotherapy combinations. Its tumors display a myeloid-dominated, relatively "cold" microenvironment with sparse T-cell infiltration that closely resembles many human bladder cancers, and the line faithfully reproduces the male predominance of the human disease through androgen-responsive growth — testosterone stimulates proliferation in vitro, and tumors progress faster in male hosts.

Fig 1. PD-1/PD-L1 kinetics in orthotopic MB49 tumors (T cells, myeloid cells, tumor cells day 5–9) and survival benefit of anti-PD1 given at day 5 vs 9 vs 12 post-MB49-luc challenge. (Domingos-Pereira, Sonia, et al., 2022)

Two implantation formats dominate practical use. The subcutaneous format is simple and rapid, with palpable flank tumors typically appearing within 7–10 days of inoculating 10⁶ cells, making it ideal for first-pass efficacy screening and straightforward volume-based monitoring. The orthotopic intravesical format is more demanding but far more instructive: after transurethral catheterization, the urothelium is briefly conditioned — for example with a few microliters of silver nitrate or an acid–alkali wash — and a suspension of roughly 10⁶ cells is instilled into the bladder lumen and retained for about an hour; published protocols report take rates approaching 97%, with tumors producing hematuria and bladder weights ten- to fifteen-fold above normal, and histology with immunohistochemistry (CK7 and CEA positivity) closely resembling human infiltrating urothelial carcinoma. Because intravesical tumors cannot be palpated until late, luciferase-tagged MB49 (MB49-luc) enables bioluminescence detection from as early as day three after instillation and longitudinal quantification of response — a capability that has underpinned pivotal preclinical studies of anti-PD-1/PD-L1 agents, BCG combinations, and intravesical cytokine and gene therapies.

Cell Line Information: MB49

MB49 (Cellosaurus CVCL_7076; Cytion catalog 305240; CancerTools 153368) is a murine urothelial carcinoma line distributed by commercial repositories and inventor institutions. The luciferase-tagged derivative MB49-luc (CancerTools 161579), generated by stable luciferase transduction, supports real-time bioluminescent tracking of tumor take, growth, and treatment response. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the MB49 syngeneic model brings the full workflow under one accountable team: authenticated, mycoplasma-free MB49 or MB49-luc cell banks are maintained at low passage, immunocompetent C57BL/6 hosts are sourced and sex-matched to study design, tumors are established by the subcutaneous or intravesical route with published take rates, and intravesical agents such as BCG, cytokines, or gene-therapy vectors are administered on schedule through catheter-based protocols — all proceeding through scheduled imaging, randomized dosing, and terminal bladder histopathology under IACUC-compliant conditions and returned as an audit-ready data package.

Workflow of MB49 Syngeneic Model Construction

MB49 studies come in two flavors — rapid subcutaneous screening and technically demanding intravesical modeling — and both reward disciplined cell preparation and sterile catheter technique. A standard program proceeds as follows.

1. Cell preparation and quality control: MB49 or MB49-luc cells are expanded at low passage, confirmed mycoplasma-free and authenticated, washed free of serum, and luciferase activity verified in vitro; inocula are prepared fresh at 10⁶ cells in 0.1 mL (subcutaneous) or 50–100 μL (intravesical).
2. Host selection and acclimation: C57BL/6 mice, typically 6–10 weeks of age and sex-matched to the study question given the model's androgen responsiveness, are quarantined and acclimated in a specific-pathogen-free barrier facility.
3. Implantation: subcutaneous route. The flank is shaved and 10⁶ cells in 0.1 mL are injected subcutaneously; the site is compressed briefly on needle withdrawal, and tumors are expected to become palpable within 7–10 days.
4. Implantation: intravesical route. Under anesthesia and after transurethral catheterization with residual urine expressed, the bladder is conditioned (for example 0.3 M AgNO₃, ~5 μL for 15 seconds, followed by PBS wash, or a brief HCl/NaOH cycle), and the cell suspension is instilled and retained for approximately one hour.
5. Recovery and confirmation of engraftment: Mice recover with analgesia and monitoring; for luciferase-tagged cohorts, bioluminescence imaging after intraperitoneal D-luciferin injection confirms tumor establishment as early as day 3, with hematuria serving as a clinical indicator of intravesical take.
6. Randomization and intravesical treatment: Mice are randomized by imaging signal or tumor volume into arms; intravesical agents (BCG, cytokine formulations, oncolytic or gene-therapy vectors) are instilled through catheter on the protocol schedule — commonly twice weekly — while body weight and clinical signs are recorded.
7. Longitudinal monitoring: Tumor burden is tracked by caliper measurement in subcutaneous studies and by serial bioluminescence imaging in orthotopic studies, with cystoscopic or bladder-weight surrogates complementing imaging where indicated.
8. Endpoint analysis and reporting: At termination, bladders are weighed and processed for H&E and immunohistochemistry (including CK7, CEA, CD8, FoxP3, and PD-L1 panels), draining lymph nodes and lungs are examined for metastasis, and all findings are consolidated into the final report.

Fig 2. MB49 Syngeneic Model construction workflow.

Case Study-MB49 Syngeneic Model Development

Alfa Cytology has applied the MB49 syngeneic platform to preclinical programs spanning checkpoint inhibitor evaluation, intravesical BCG combination strategies, cytokine and gene-therapy formulations, and photothermal-immunotherapy approaches in bladder cancer. In these engagements, longitudinal bioluminescence imaging quantified orthotopic tumor establishment and treatment response in individual animals, while terminal bladder histopathology with immune-marker panels completed the pharmacological and immunological assessment. Study parameters — implantation route, sex of hosts, instillation schedules, and endpoint panels — are configured to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

MB49 work succeeds on three capabilities that many providers treat as afterthoughts: authenticated syngeneic cell stewardship, sterile transurethral catheter technique, and immunologically literate endpoints. Alfa Cytology fields all three in-house, making the MB49 syngeneic model a dependable backbone for your bladder cancer program.

• Two validated implantation formats — rapid subcutaneous screening and true intravesical orthotopic modeling — under one roof.
• Proficient intravesical dosing, including scheduled catheter-based BCG, cytokine, and gene-therapy administration.
• Authentic immunocompetent biology, with a myeloid-rich "cold" microenvironment that mirrors human bladder tumors.
• Sex-aware study design, leveraging the model's androgen responsiveness to model male-predominant disease.
• Early, quantitative engraftment confirmation by bioluminescence imaging from day 3 onward.
• Immunologically deep endpoints, including CD8, FoxP3, and PD-L1 immunohistochemistry panels.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your bladder cancer program needs an immunocompetent syngeneic platform, contact us today to discuss implantation route, host sex, instillation schedules, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.